Toll Free: 1-888-928-9744

Female Sexual Dysfunction - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Female Sexual Dysfunction - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2016, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 6, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Female Sexual Dysfunction Overview 8 Therapeutics Development 9 Pipeline Products for Female Sexual Dysfunction - Overview 9 Pipeline Products for Female Sexual Dysfunction - Comparative Analysis 10 Female Sexual Dysfunction - Therapeutics under Development by Companies 11 Female Sexual Dysfunction - Therapeutics under Investigation by Universities/Institutes 12 Female Sexual Dysfunction - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Female Sexual Dysfunction - Products under Development by Companies 16 Female Sexual Dysfunction - Products under Investigation by Universities/Institutes 17 Female Sexual Dysfunction - Companies Involved in Therapeutics Development 18 Allergan Plc 18 Apricus Biosciences Inc 19 Emotional Brain BV 20 Fabre-Kramer Pharmaceuticals Inc 21 GlaxoSmithKline Plc 22 M et P Pharma AG 23 Palatin Technologies Inc 24 Re-Pharm Ltd 25 TherapeuticsMD Inc 26 Valeant Pharmaceuticals International Inc 27 Female Sexual Dysfunction - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 (sildenafil citrate + testosterone) - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 AB-101 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 alprostadil - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 bremelanotide - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 estradiol acetate - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 FKW-00GA - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 gepirone hydrochloride ER - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 S1B-3006 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 S1B-307 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 SIP-104 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecule for Sexual Dysfunction - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Small Molecules to Agonize Dopamine D2 Receptor for Sexual Dysfunction - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 SPT-201 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 TBS-2 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 WC-3011 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Female Sexual Dysfunction - Dormant Projects 70 Female Sexual Dysfunction - Discontinued Products 72 Female Sexual Dysfunction - Product Development Milestones 73 Featured News & Press Releases 73 Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder 73 Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine 74 Sep 22, 2016: TherapeuticsMD Announces Multiple Presentations Related to Yuvvexy (TX-004HR) at Two Upcoming Medical Conferences 74 Sep 19, 2016: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy (TX-004HR) 76 Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder 76 Jul 07, 2016: TherapeuticsMD Announces New Drug Application Submission for Yuvvexy (TX-004HR) 77 Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies' New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors 77 Jun 29, 2016: TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application 77 May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial 78 Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences 78 Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 79 Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting 79 Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction 80 Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction 80 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 82 Disclaimer 83
List of Tables
Number of Products under Development for Female Sexual Dysfunction, H2 2016 9 Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Female Sexual Dysfunction - Pipeline by Allergan Plc, H2 2016 18 Female Sexual Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2016 19 Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2016 20 Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016 21 Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H2 2016 22 Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2016 23 Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H2 2016 24 Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2016 25 Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2016 26 Female Sexual Dysfunction - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Assessment by Combination Products, H2 2016 29 Number of Products by Stage and Target, H2 2016 31 Number of Products by Stage and Mechanism of Action, H2 2016 33 Number of Products by Stage and Route of Administration, H2 2016 35 Number of Products by Stage and Molecule Type, H2 2016 37 Female Sexual Dysfunction - Dormant Projects, H2 2016 70 Female Sexual Dysfunction - Dormant Projects (Contd..1), H2 2016 71 Female Sexual Dysfunction - Discontinued Products, H2 2016 72



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify